Chinese (SSE) Biotech Industry Analysis
UpdatedMar 27, 2023
DataAggregated Company Financials
Companies75
- 7D-0.3%
- 3M1.5%
- 1Y-19.7%
- YTD-1.7%
Over the last 7 days, the Biotech industry has remained flat, although notably Chongqing Zhifei Biological Products declined by 4.3%. Unfortunately though, the industry is down 20% over the past 12 months. Looking forward, earnings are forecast to grow by 28% annually.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 27 Mar 2023 | CN¥1.2t | CN¥185.5b | CN¥36.7b | 40.8x | 33.6x | 6.7x |
| Wed, 22 Feb 2023 | CN¥1.3t | CN¥179.6b | CN¥37.9b | 43.1x | 34.3x | 7.2x |
| Fri, 20 Jan 2023 | CN¥1.3t | CN¥179.3b | CN¥38.3b | 42.9x | 35.1x | 7.5x |
| Sun, 18 Dec 2022 | CN¥1.3t | CN¥175.6b | CN¥37.9b | 40.7x | 33.2x | 7.2x |
| Tue, 15 Nov 2022 | CN¥1.3t | CN¥175.5b | CN¥37.9b | 39.9x | 33.3x | 7.2x |
| Thu, 13 Oct 2022 | CN¥1.1t | CN¥174.4b | CN¥40.2b | 29.5x | 27.3x | 6.3x |
| Sat, 10 Sep 2022 | CN¥1.2t | CN¥183.4b | CN¥40.0b | 34x | 30.7x | 6.7x |
| Mon, 08 Aug 2022 | CN¥1.3t | CN¥171.1b | CN¥43.3b | 35.4x | 29.4x | 7.4x |
| Wed, 06 Jul 2022 | CN¥1.4t | CN¥168.1b | CN¥42.4b | 40.6x | 32.6x | 8.2x |
| Fri, 03 Jun 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 36.7x | 27.9x | 7x |
| Sun, 01 May 2022 | CN¥1.2t | CN¥166.7b | CN¥43.0b | 36.9x | 28x | 7.2x |
| Tue, 29 Mar 2022 | CN¥1.4t | CN¥155.0b | CN¥41.5b | 43.7x | 34.8x | 9.3x |
| Thu, 24 Feb 2022 | CN¥1.4t | CN¥149.8b | CN¥40.2b | 44.4x | 35.2x | 9.5x |
| Sat, 22 Jan 2022 | CN¥1.4t | CN¥143.3b | CN¥39.3b | 45.8x | 36.4x | 10x |
| Mon, 20 Dec 2021 | CN¥1.6t | CN¥141.8b | CN¥39.1b | 48.3x | 40x | 11x |
| Wed, 17 Nov 2021 | CN¥1.6t | CN¥145.1b | CN¥40.2b | 47.4x | 39.5x | 10.9x |
| Fri, 15 Oct 2021 | CN¥1.6t | CN¥132.1b | CN¥34.7b | 47.2x | 45.6x | 12x |
| Sun, 12 Sep 2021 | CN¥1.6t | CN¥130.3b | CN¥33.4b | 46.6x | 46.8x | 12x |
| Tue, 10 Aug 2021 | CN¥1.8t | CN¥130.3b | CN¥33.4b | 53.6x | 53.5x | 13.7x |
| Mon, 03 May 2021 | CN¥1.8t | CN¥116.0b | CN¥27.4b | 58.6x | 66.5x | 15.7x |
| Thu, 04 Feb 2021 | CN¥1.6t | CN¥102.3b | CN¥22.7b | 54.5x | 69.4x | 15.4x |
| Sun, 08 Nov 2020 | CN¥1.6t | CN¥90.5b | CN¥18.1b | 72.8x | 87.9x | 17.6x |
| Sat, 01 Aug 2020 | CN¥1.9t | CN¥81.4b | CN¥14.5b | 102.5x | 131.3x | 23.4x |
| Tue, 05 May 2020 | CN¥866.1b | CN¥67.3b | CN¥9.1b | 66.7x | 94.8x | 12.9x |
Price to Earnings Ratio
86.3x
Current Industry PE
- Investors are pessimistic on the Chinese Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 33.6x which is lower than its 3-year average PE of 56.6x.
- The 3-year average PS ratio of 12.0x is higher than the industry's current PS ratio of 6.7x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have grown 61% per year over the last three years.
- Revenues for these companies have grown 41% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 1.87% | |
| Healthcare | -0.44% | |
| Biotech | -0.25% | |
| Biotech | -0.25% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603392 Beijing Wantai Biological Pharmacy Enterprise | CN¥118.79 | 4.0% +CN¥4.1b | -36.4% | PE22.7x | |
| 300676 BGI Genomics | CN¥63.19 | 10.0% +CN¥2.3b | -22.9% | PE32.6x | |
| 403 Pacific Shuanglin Bio-pharmacy | CN¥24.21 | 10.5% +CN¥1.7b | 11.4% | PE40.6x | |
| 603087 Gan & Lee Pharmaceuticals | CN¥37.18 | 3.7% +CN¥752.3m | -28.7% | PE125.5x | |
| 2007 Hualan Biological Engineering | CN¥22.11 | 1.8% +CN¥729.7m | -1.1% | PE35.4x |